Disposition of patients. Studies 06–008 and 06–009 were concurrent phase 3, double-blind, placebo-controlled, clinical trials; 06–010 is the open-label extension of the phase 3 trials. The denominator for studies 06–008 and 06–009 is the number of randomized patients, and the denominator for 06–010 is the number of treated patients. *Denominator is the number of completed patients from 06–008/06–009. PBO, placebo; SXB, sodium oxybate.